Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients
暂无分享,去创建一个
Wu Zhu | Wei Zhang | Xiang Chen | Wei Zhang | Xiang Chen | Cong Peng | Wangqing Chen | C. Peng | Xu Zhang | Xu Zhang | Wangqing Chen | Wu Zhu
[1] Weihua Huang,et al. Validation of a Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Method for Determination of All-Trans Retinoic Acid in Human Plasma and Its Application to a Bioequivalence Study , 2014, Molecules.
[2] Jochen Schmitt,et al. The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis , 2005, Dermatology.
[3] Wei Zhang,et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. , 2012, British journal of clinical pharmacology.
[4] I. Song,et al. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake , 2012, Biopharmaceutics & drug disposition.
[5] J. Polli,et al. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). , 2013, Toxicology and applied pharmacology.
[6] A. Schinkel,et al. Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.
[7] S. Feldman,et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. , 2004, Journal of the American Academy of Dermatology.
[8] A. Arechalde,et al. Management of Psoriasis , 2000, BioDrugs.
[9] A. Ormerod,et al. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology , 2010, The British journal of dermatology.
[10] P. Neuvonen,et al. Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.
[11] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[12] Xiang Chen,et al. The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis. , 2018, Personalized medicine.
[13] S. Dogra,et al. Acitretin in psoriasis: an evolving scenario , 2014, International journal of dermatology.
[14] Jemma C. Hopewell,et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study , 2012, European heart journal.
[15] Y. Kanai,et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. , 2004, Biochemical and biophysical research communications.
[16] VDR gene polymorphisms are associated with the clinical response to calcipotriol in psoriatic patients. , 2015, Journal of dermatological science.
[17] V. Patravale,et al. Psoriasis clinical implications and treatment: a review. , 2013, Critical reviews in therapeutic drug carrier systems.
[18] HighWire Press,et al. Drug metabolism and disposition : the biological fate of chemicals. , 1973 .
[19] Conrad C. Huang,et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] A review , 2019 .
[21] Y. Maehara,et al. Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients , 2014, Journal of Gastroenterology.
[22] F. Fahrenholz,et al. Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein , 2012, Neurodegenerative Diseases.
[23] M. Hayden,et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.
[24] William E. Evans,et al. Pharmacogenomics in the clinic , 2015, Nature.
[25] Praveen M. Bahadduri,et al. Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.
[26] J. M. Carrascosa,et al. Acitretina: guía de uso en psoriasis , 2013 .
[27] Shuang Zhao,et al. Frizzled-related proteins 4 (SFRP4) rs1802073G allele predicts the elevated serum lipid levels during acitretin treatment in psoriatic patients from Hunan, China , 2018, PeerJ.
[28] D. Tang-Liu,et al. Clinical Pharmacokinetics and Drug Metabolism of Tazarotene , 1999, Clinical pharmacokinetics.
[29] M. Corazza,et al. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. , 2015, Acta dermato-venereologica.
[30] W. Cao,et al. Acitretin exerted a greater influence on T‐helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris , 2012, The Journal of dermatology.
[31] Wu Zhu,et al. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis , 2017, GigaScience.
[32] K. Maeda,et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.
[33] Martin C. Müller,et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. , 2013, Blood.
[34] S. Feldman,et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. , 2006, Archives of dermatology.
[35] F. Vanaclocha,et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.
[36] M. Pirmohamed,et al. SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink , 2013, Clinical pharmacology and therapeutics.
[37] M. Detmar,et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. , 2006, The Journal of investigative dermatology.
[38] Min Zhang,et al. Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells , 2008, Archives of Dermatological Research.